scholarly journals Access to oncology consultation in a cancer cohort in northeastern Ontario

2015 ◽  
Vol 22 (2) ◽  
pp. 69 ◽  
Author(s):  
M. Conlon ◽  
M. Hartman ◽  
B. Ballantyne ◽  
N. Aubin ◽  
M. Meigs ◽  
...  
Keyword(s):  
Cancer Diagnosis ◽  
Radiation Oncology ◽  
Population Based ◽  
Primary Cancer ◽  
Ontario Health Insurance Plan ◽  
Cancer Data ◽  
Disease Trajectory ◽  
Area Of Interest ◽  
Cancer Symptom Management ◽  
Rural Patients

BackgroundTo enhance cancer symptom management for residents of Sudbury–Manitoulin District, an ambulatory palliative clinic (pac) was established at the Northeast Cancer Centre of Health Sciences North. The pac is accessed from a medical or radiation oncology consultation. The primary purpose of the present population-based retrospective study was to estimate the percentage of cancer patients who died without ever having a medical or radiation oncology consultation. A secondary purpose was to determine factors associated with never having received one of those specialized consultations.MethodsAdministrative data was obtained through the Ontario Cancer Data Linkage Project. For each index case, we constructed a timeline, in days, of all Ontario Health Insurance Plan billing codes and associated service dates starting with the primary cancer diagnosis and ending with death.ResultsWithin the 5-year study period (2004–2008), 6683 people in the area of interest with a valid record of primary cancer diagnosis died from any cause. Most (n = 5988, 89.6%) had 1 primary cancer diagnosis. For that subgroup, excluding those with a disease duration of 0 days (n = 67), about 18.4% (n = 1088) never had a consultation with a medical or radiation oncologist throughout their disease trajectory. Patients who were older or who resided in a rural area were significantly less likely to have had a consultation.ConclusionsSpecific strategies directed toward older and rural patients might help to address this important access-to-care issue.

scholarly journals Access to cancer care in northwestern Ontario—a population-based study using administrative data

2020 ◽  
Vol 27 (3) ◽  
Author(s):  
M. Febbraro ◽  
M. Conlon ◽  
J. Caswell ◽  
N. Laferriere
Keyword(s):  
Administrative Data ◽  
Urban Areas ◽  
Access To Health Care ◽  
Universal Access ◽  
Population Based ◽  
Ontario Health Insurance Plan ◽  
Cancer Data ◽  
Factors Associated ◽  
Specialist Consultation ◽  
Northwestern Ontario

Background: Despite universal access to health care in Canada, disparities exist relating to social determinants of health, which contribute to discrepancies in cancer incidence and outcomes between rural and urban areas. Given that Canada has one of the highest-quality national population-based cancer registry systems in the world and there is little information regarding cancer statistics specific to northwestern Ontario, the purpose of this study was to estimate the percentage of cancer patients without documentation of a specialist consultation (medical or radiation oncology consultation) and to determine factors that affect access to specialist consultation in northwestern Ontario. Methods: This was a population-based retrospective study using administrative data. Administration data was obtained through the Ontario Cancer Data Linkage Project. For each index case, a timeline was constructed of all Ontario Health Insurance Plan billing codes and associated service dates starting with primary cancer diagnosis and ending with death. Specific factors affecting access to specialist consultation were assessed. Results: Within the 6 year study period (2010-2016), 2583 index cases were identified. Most (n=2007, 78%) received a specialist consultation. Factors associated with not receiving a specialist consultation included older age (p<0.0001, OR 0.29; 95% CI 0.19-0.44) and rural residence (p<0.0001, OR 0.48; 95% CI 0.48-0.72). Factors associated with receiving a specialist consultation included increased duration of disease (p< 0.0001, OR 1.32; 95% CI 1.19-1.46), a diagnosis of breast cancer (p < 0.0001, OR 2.51; 95% CI 1.43-4.42), and a diagnosis of lung cancer (p< 0.0001, OR 1.77; 95% CI 1.38-2.26).   Conclusions: These findings are consistent with the other studies assessing access to care barriers, but is the first to look at care access in northwestern Ontario. Further research is needed to examine gaps in care relating to access to primary referral services, symptom recognition, cancer screening, and travel associated burdens specific to northwestern Ontario.

Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study

2017 ◽  
Vol 77 (4) ◽  
pp. 510-514 ◽  
Author(s):  
Lene Dreyer ◽  
René L Cordtz ◽  
Inger Marie J Hansen ◽  
Lars Erik Kristensen ◽  
Merete L Hetland ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cancer Diagnosis ◽  
Malignant Neoplasm ◽  
Population Based ◽  
Cancer Site ◽  
Primary Cancer ◽  
Second Malignant Neoplasm ◽  
Increased Risk ◽  
Before And After ◽  
History Of

ObjectiveTo study the risk of a second malignant neoplasm (SMN) and mortality in patients with rheumatoid arthritis (RA) with a history of a primary cancer diagnosis and treated with biological disease-modifying antirheumatic drugs (bDMARD).MethodsAmong patients with RA (n=15 286) registered in the DANBIO Register during 2000–2011, 1678 had a primary cancer according to the Danish Cancer Registry. HRs for SMN and death were calculated.ResultsDuring follow-up there were 279 patients with RA contributing person-years to the bDMARDs use before their primary cancer diagnosis, 220 to the only after, 92 to the both before and after, while 1203 patients with RA contributed to the non-use strata. Ever use of bDMARDs was associated with a HR of 1.11 (95% CI 0.74 to 1.67) for developing a SMN compared with non-use (cancer site adjusted). The HR for death associated with bDMARD use before the primary cancer diagnosis was increased 1.53 (95% CI 1.13 to 2.09). After further adjustment for extent of the primary cancer, the HR for death was 1.20 (95% CI 0.88 to 1.63) for bDMARDs use before cancer, 1.36 (95% CI 0.78 to 2.39) for bDMARD use only after cancer and 1.22 (95% CI 0.70 to 2.13) for use both before and after the cancer.ConclusionsAmong patients with RA with a history of cancer, treatment with bDMARDs was not associated with increased risk of SMN. No clear conclusion can be drawn regarding mortality in bDMARD-treated patients with RA.

The Introduction of Hospital-Based Cancer Registries in Queensland

1989 ◽  
Vol 19 (1) ◽  
pp. 7-9 ◽  
Author(s):  
Sue Walker ◽  
Sheree Lloyd ◽  
Josie Parisi ◽  
Sari Sirvio
Keyword(s):  
Data Management ◽  
Medical Record ◽  
Cancer Registry ◽  
Health Department ◽  
Cancer Registries ◽  
Population Based ◽  
Support Network ◽  
Cancer Data ◽  
Cancer Registry Data ◽  
Area Of Interest

The management of cancer data is an expanding area of interest and employment for medical record administrators in Queensland. This is largely due to the software package and support network for hospital-based cancer registries that has been developed by the Data Management Unit of the Epidemiology and Prevention Unit in the State Health Department. The package is offered to any hospital interested in setting up and maintaining their own cancer data base and is completely compatible with the information requirements of the Queensland population-based registry. This paper describes the development of a hospital-based cancer registry system and the involvement of medical record administrators in cancer registry data management. (AMRJ 19(1), 6–8).

Statin Use After Colorectal Cancer Diagnosis and Survival: A Population-Based Cohort Study

2014 ◽  
Vol 32 (28) ◽  
pp. 3177-3183 ◽  
Author(s):  
Chris R. Cardwell ◽  
Blanaid M. Hicks ◽  
Carmel Hughes ◽  
Liam J. Murray
Keyword(s):  
Colorectal Cancer ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Practice Research ◽  
Mortality Data ◽  
Clinical Practice Research Datalink ◽  
Cancer Data ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Statin Use

Purpose To investigate whether statins used after colorectal cancer diagnosis reduce the risk of colorectal cancer-specific mortality in a cohort of patients with colorectal cancer. Patients and Methods A cohort of 7,657 patients with newly diagnosed stage I to III colorectal cancer were identified from 1998 to 2009 from the National Cancer Data Repository (comprising English cancer registry data). This cohort was linked to the United Kingdom Clinical Practice Research Datalink, which provided prescription records, and to mortality data from the Office of National Statistics (up to 2012) to identify 1,647 colorectal cancer–specific deaths. Time-dependent Cox regression models were used to calculate hazard ratios (HR) for cancer-specific mortality and 95% CIs by postdiagnostic statin use and to adjust these HRs for potential confounders. Results Overall, statin use after a diagnosis of colorectal cancer was associated with reduced colorectal cancer–specific mortality (fully adjusted HR, 0.71; 95% CI, 0.61 to 0.84). A dose-response association was apparent; for example, a more marked reduction was apparent in colorectal cancer patients using statins for more than 1 year (adjusted HR, 0.64; 95% CI, 0.53 to 0.79). A reduction in all-cause mortality was also apparent in statin users after colorectal cancer diagnosis (fully adjusted HR, 0.75; 95% CI, 0.66 to 0.84). Conclusion In this large population-based cohort, statin use after diagnosis of colorectal cancer was associated with longer rates of survival.

scholarly journals Su1228 Increased Risk of Colorectal Cancer in Patients With Prior Ovarian Cancer Diagnosis: A Population Based US Study

2014 ◽  
Vol 146 (5) ◽  
pp. S-408
Author(s):  
Yezaz A. Ghouri ◽  
Sachin Batra ◽  
Nirav C. Thosani ◽  
Sushovan Guha
Keyword(s):  
Colorectal Cancer ◽  
Ovarian Cancer ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Increased Risk

scholarly journals Colonoscopy and Flexible Sigmoidoscopy Practice Patterns in Ontario: A Population-Based Study

2007 ◽  
Vol 21 (7) ◽  
pp. 431-434 ◽  
Author(s):  
Susan E Schultz ◽  
Chris Vinden ◽  
Linda Rabeneck
Keyword(s):  
Flexible Sigmoidoscopy ◽  
Practice Patterns ◽  
Age Groups ◽  
Population Based ◽  
Insurance Plan ◽  
Ontario Health Insurance Plan ◽  
Population Based Study ◽  
The North ◽  
General Surgeons ◽  
Statistics Canada

OBJECTIVE: To conduct a population-based study on the provision of large bowel endoscopic services in Ontario.METHODS: Data from the following databases were analyzed: the Ontario Health Insurance Plan, the Institute for Clinical Evaluative Sciences Physicians Database and Statistics Canada. The flexible sigmoidoscopy and colonoscopy rates per 10,000 persons (50 to 74 years of age) by region between April 1, 2001, and March 31, 2002, were calculated, as well as the numbers and types of physicians who performed each procedure.RESULTS: In 2001/2002, a total of 172,108 colonoscopies and 43,400 flexible sigmoidoscopies were performed in Ontario for all age groups. The colonoscopy rate was approximately five times that of flexible sigmoidoscopy; rates varied from 463.1 colonoscopies per 10,000 people in the north to 286.8 colonoscopies per 10,000 people in the east. Gastroenterologists in all regions tended to perform more procedures per physician, but because of the large number of general surgeons, the total number of procedures performed by each group was almost the same.CONCLUSION: Population-based rates of colonoscopies and flexible sigmoidoscopies are low in Ontario, as are the procedure volumes of approximately one-quarter of physicians.

scholarly journals Familial colorectal cancer risk by subsite of primary cancer: a population-based study in Utah

2015 ◽  
Vol 41 (6) ◽  
pp. 573-580 ◽  
Author(s):  
N. J. Samadder ◽  
K. R. Smith ◽  
G. P. Mineau ◽  
R. Pimentel ◽  
J. Wong ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Risk ◽  
Population Based ◽  
Colorectal Cancer Risk ◽  
Primary Cancer ◽  
Familial Colorectal Cancer ◽  
Population Based Study

Unemployment risk at 2 and 4 years following colorectal cancer diagnosis: a population based study

2016 ◽  
Vol 69 ◽  
pp. 70-76 ◽  
Author(s):  
Yakir Rottenberg ◽  
Navah Z. Ratzon ◽  
Miri Cohen ◽  
Ayala Hubert ◽  
Beatrice Uziely ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Population Based Study ◽  
Unemployment Risk

scholarly journals Survival of patients with synchronous brain metastases: an epidemiological study in southeastern Michigan

2000 ◽  
Vol 9 (2) ◽  
pp. 1-5 ◽  
Author(s):  
Ajith J. Thomas ◽  
Jack P. Rock ◽  
Christine C. Johnson ◽  
Linda Weiss ◽  
Gordon Jacobsen ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Median Survival ◽  
Cancer Diagnosis ◽  
Systemic Disease ◽  
Primary Source ◽  
Primary Site ◽  
Unknown Primary ◽  
Primary Cancer ◽  
Significant Difference ◽  
Frequent Site

Object It has been suggested that synchronous brain metastases (that is, those occurring within 2 months of primary cancer diagnosis) are associated with a shorter survival time compared with metachronous lesions (those occurring greater than 2 months after primary cancer diagnosis). In this study the authors used data obtained from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program to determine the incidence of synchronous brain metastases and length of survival of patients in a defined population of southeastern Michigan residents. Methods Data obtained in 2682 patients with synchronous brain metastases treated from 1973 to 1995 were reviewed. Study criteria included patients in whom at least one brain metastasis was diagnosed within 2 months of the diagnosis of primary cancer and those with an unknown primary source. The incidence per 100,000 increased fivefold, from 0.69 in 1973 to 3.83 in 1995. The most frequent site for the primary cancer was the lung (75.4%). The second largest group (10.7%) consisted of patients in whom the primary site was unknown. The median survival length was 3.3 months. There was no significant difference in the median survival in patients with primary lung/bronchus and those with an unknown primary site (3.2 months and 3.4 months, respectively). Conclusions Patients who present with synchronous lesions have a poor prognosis, and the predominant cause of death, in greater than 90% of cases, is related to systemic disease; however, despite poor median survival lengths, certain patients will experience prolonged survival.

Sign in / Sign up

Export Citation Format

Share Document